7-hydroxy-1-vinyl-naphthalene | 497151-66-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7-hydroxy-1-vinyl-naphthalene
• 英文别名: 8-vinyl-2-naphthol；8-ethenylnaphthalen-2-ol
• CAS: 497151-66-3
• 化学式: C₁₂H₁₀O
• 分子量: 170.211
• InChiKey: JOPFSIVFVOJZSV-UHFFFAOYSA-N

物化性质

• 沸点：
  337.6±11.0 °C(Predicted)
• 密度：
  1.150±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-hydroxy-1-vinyl-naphthalene 在 咪唑 、 chromium(VI) oxide 、 4-二甲氨基吡啶 、 过碘酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 9-硼双环[3.3.1]壬烷 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 44.0h， 生成 N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(7-hydroxy-1-naphthyl)acetamide
  参考文献：
  名称：

  Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence

  摘要：

  We have identified naphthol derivatives as inhibitors of the vanilloid receptor TRPV1 by high throughput screening. The initial lead showed high clearance in rats and has been optimized by enhancing the acidity of the phenol group. Compound 6b has reduced clearance, improved potency and is active in rat cystometry models of urinary incontinence after intravenous administration. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.013
• 作为产物：
  描述：

  1-氨基-7-萘酚 、 三丁基乙烯基锡 在 potassium iodide 、 sodium nitrite 、 四(三苯基膦)钯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 17.0h， 生成 7-hydroxy-1-vinyl-naphthalene
  参考文献：
  名称：

  Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence

  摘要：

  We have identified naphthol derivatives as inhibitors of the vanilloid receptor TRPV1 by high throughput screening. The initial lead showed high clearance in rats and has been optimized by enhancing the acidity of the phenol group. Compound 6b has reduced clearance, improved potency and is active in rat cystometry models of urinary incontinence after intravenous administration. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.013

文献信息

• Tandem Iridium Catalysis as a General Strategy for Atroposelective Construction of Axially Chiral Styrenes
  作者：Jie Wang、Xiaotian Qi、Xiao-Long Min、Wenbin Yi、Peng Liu、Ying He

  DOI：10.1021/jacs.1c04400

  日期：2021.7.21

  Axially chiral styrenes are of great interest since they may serve as a class of novel chiral ligands in asymmetric synthesis. However, only recently have strategies been developed for their enantioselective preparation. Thus, the development of novel and efficient methodologies is highly desirable. Herein, we reported the first tandem iridium catalysis as a general strategy for the synthesis of axially

  轴向手性苯乙烯很受关注，因为它们可以在不对称合成中作为一类新的手性配体。然而，直到最近才开发出用于它们的对映选择性制备的策略。因此，非常需要开发新颖有效的方法。在此，我们报道了第一个串联铱催化作为合成轴向手性苯乙烯的通用策略，该方法通过不对称烯丙基取代异构化( AASI ) 使用碳酸肉桂酯类似物作为亲电子试剂和萘酚作为亲核试剂。在这种方法中，轴向手性苯乙烯是通过两个独立的铱催化循环产生的：铱催化的不对称烯丙基取代和原位通过由相同的铱催化剂催化的立体有择的 1,3-氢化物转移进行异构化。实验和计算研究都表明，异构化是通过铱催化的苄基 C-H 键氧化加成，然后是末端 C-H 还原消除来进行的。在中心到轴向的手性转移中，萘酚的羟基通过与 Ir(I) 中心协调在确保立体特异性方面发挥着至关重要的作用。该过程适应广泛的官能团兼容性。产物以极好的收率产生，具有极好的对映选择性，可以转化为各种轴向手性分子。
• Fluorine-Containing Compound, Fluorine-Containing Polymer, Negative-Type Resist Composition, and Patterning Process Using Same
  申请人：ISONO Yoshimi

  公开号：US20120226070A1

  公开（公告）日：2012-09-06

  A fluorine-containing unsaturated carboxylic acid represented by formula (1), wherein R 1 represents a polymerizable double-bond containing group, R 3 represents a fluorine atom or fluorine-containing alkyl group, and W represents a bivalent linking group. This compound can provide a fluorine-containing polymer compound that has a weight-average molecular weight of 1,000-1,000,000 and contains a repeating unit represented by formula (2), wherein R 3 and W are defined as above, each of R 4 , R 5 and R 6 independently represents a hydrogen atom, fluorine atom or monovalent organic group, at least two of R 4 , R 5 and R 6 may be combined to form a ring. This polymer compound can provide a chemically amplified resist composition that is transparent to KrF or ArF excimer laser light and has a high resolution and is capable of forming a pattern having a rectangular section with no swelling.

  化学式（1）所表示的含氟不饱和羧酸，其中R1代表可聚合的双键含基团，R3代表氟原子或含氟烷基团，W代表二价连接基团。该化合物可提供一种分子量为1,000-1,000,000且含有化学式（2）所表示的重复单元的含氟聚合物化合物，其中R3和W如上所定义，R4、R5和R6中的每一个独立地代表氢原子、氟原子或一价有机基团，R4、R5和R6中至少有两个可以结合形成环。该聚合物化合物可提供一种化学增强型光刻胶组合物，该组合物对KrF或ArF准分子激光光线透明，具有高分辨率，并能够形成具有矩形截面且无膨胀的图案。
• [EN] NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS<br/>[FR] DERIVES AMINES
  申请人：BAYER AG

  公开号：WO2003014064A1

  公开（公告）日：2003-02-20

  Naphthylurea and naphthylacetamide derivatives of formula (I) which have vanilloid receptor 1 (VR1) antagonistic activity are disclosed, formula (I) wherein Y represents formula (II) and formula (III) and the variables Q, X, R6, R7, R8, R8a, R9, R10 and R11 are as defined in the claims. The compounds are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.

  本文披露了公式(I)的萘基脲和萘基乙酰胺衍生物，其具有vanilloid受体1（VR1）拮抗活性，其中公式(I)中Y代表公式(II)和公式(III)，而变量Q、X、R6、R7、R8、R8a、R9、R10和R11如权利要求中所定义。这些化合物可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、过度活动膀胱、慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁和/或炎症性疾病。
• Amine derivatives
  申请人：——

  公开号：US20040259875A1

  公开（公告）日：2004-12-23

  An amine derivative, its tautomeric or stereoisomeric form, or a salt thereof which has vanilloid receptor 1 (VR1) antagonistic activity, is disclosed. The amine derivative has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.

  本发明揭示了一种具有vanilloid receptor 1（VR1）拮抗活性的胺衍生物、其互变异构体或立体异构体形式或其盐。该胺衍生物具有优异的VR1拮抗活性，适用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、过度活动膀胱、慢性疼痛、神经痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁和/或炎症性疾病。
• NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS
  申请人：Bayer HealthCare AG

  公开号：EP1414788A1

  公开（公告）日：2004-05-06